This clinical trial is focused on studying the effects of a treatment called Odronextamab in patients with a type of cancer known as B-cell non-Hodgkin lymphoma. This type of cancer affects the lymphatic system, which is part of the body’s immune system. The study is specifically looking at patients whose cancer has returned or has not responded to previous treatments. The treatment being tested, Odronextamab, is a special kind of medication known as a bispecific antibody, which is designed to target and attack cancer cells.

The purpose of the study is to evaluate how well Odronextamab works in shrinking tumors and to assess its safety in patients. The study includes several subtypes of B-cell non-Hodgkin lymphoma, such as follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and marginal zone lymphoma. Patients participating in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the patients over a period of time to see how their cancer responds to the treatment and to check for any side effects.

Throughout the study, researchers will collect information on how the cancer responds to Odronextamab and any changes in the patients’ health. This information will help determine the effectiveness of the treatment and its potential as a new option for patients with B-cell non-Hodgkin lymphoma. The study aims to provide valuable insights into the treatment of this type of cancer and improve future care for patients. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.